21 CFR § 203.10 - Restrictions on reimportation.

---
identifier: "/us/cfr/t21/s203.10"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "21 CFR § 203.10 - Restrictions on reimportation."
title_number: 21
title_name: "Food and Drugs"
section_number: "203.10"
section_name: "Restrictions on reimportation."
chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "C"
subchapter_name: "DRUGS: GENERAL"
part_number: "203"
part_name: "PRESCRIPTION DRUG MARKETING"
positive_law: false
currency: "2026-04-05"
last_updated: "2026-04-05"
format_version: "1.1.0"
generator: "[email protected]"
authority: "21 U.S.C. 331, 333, 351, 352, 353, 360, 371, 374, 381."
regulatory_source: "64 FR 67756, Dec. 3, 1999, unless otherwise noted."
cfr_part: "203"
---


# 203.10 Restrictions on reimportation.

No prescription drug or drug composed wholly or partly of insulin that was manufactured in a State and exported from the United States may be reimported by anyone other than its manufacturer, except that FDA may grant permission to a person other than the manufacturer to reimport a prescription drug or insulin-containing drug if it determines that such reimportation is required for emergency medical care.